Alizyme to start Phase IIb

Alizyme (LSE:AZM) will begin a 500-patient Phase IIb trial

Read the full 93 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE